Under the terms of the agreement, Mingyuan will serve as the exclusive distributor in China and Hong Kong of a series of newborn screening products being developed for the diagnosis of genetic disorders. Mingyuan also will distribute Luminex analyzers in China and Hong Kong.
The newborn screening tests to be distributed by Mingyuan will be developed by Luminex utilizing proprietary xMAP technology. Instead of detecting each genetic disorder one at a time, Luminex’s proprietary multiplexing xMAP technology is said to analyze up to 100 unique assays within a single sample, making the large-scale screening more efficient, accurate and less costly.
Chien Hoe Yong, Henry, CEO and executive director of Mingyuan, said: “Accurate and efficient newborn screening is essential to good pediatric care. With Luminex’s xMAP technology, we can quickly and precisely screen infants for many genetic disorders at once. The technology and new tests being developed will help us advance the accuracy and speed of newborn screening across China and Hong Kong.”